Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019
Author:
Affiliation:
1. Department of Health Statistics Second Military Medical University Shanghai China
2. Tongji University School of Medicine Shanghai China
3. Beijing Bioknow Information Technology Co.Ltd. Beijing China
Publisher
Wiley
Subject
Cancer Research,Oncology,Hematology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2743
Reference36 articles.
1. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
2. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
3. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
4. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
5. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials;Clinical Oncology;2024-10
2. Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis;Critical Reviews in Oncology/Hematology;2024-08
3. Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-05-07
4. Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study;Frontiers in Pharmacology;2023-10-31
5. Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma;Frontiers in Immunology;2023-07-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3